New Blood-Based Cancer Test to Transform Indian Oncology

Guardant Health and Zydus Lifesciences are preparing to launch a sophisticated multi-cancer detection test in India. This innovative blood-based diagnostic tool, called Shield, targets early-stage detection for several solid tumors. Consequently, clinicians can identify malignancies like gastric, esophageal, and liver cancers before symptoms appear. Because India faces high rates of late-stage diagnosis, this technology represents a significant advancement in oncology care.

Advancing Screening with the Multi-cancer Detection Test

The Shield test utilizes advanced liquid biopsy technology to analyze tumor DNA circulating in the blood. Therefore, it provides a less invasive alternative to traditional tissue biopsies while offering a comprehensive view of mutations. Moreover, the test is an extension of Guardant’s FDA-approved colorectal cancer screening technology. This expansion allows doctors to screen for pancreatic, bladder, and breast cancers through a single blood draw. Additionally, early detection through this method can improve survival rates by up to ten times.

Strategic Implementation in the Indian Healthcare Market

Guardant is currently collaborating with Zydus Lifesciences and various hospital chains to roll out the service. Furthermore, they are establishing pricing models to ensure institutional accessibility across major cities. Since many cancers lack established screening protocols, this test fills a critical diagnostic gap. Ultimately, the partnership aims to reduce the mortality-to-incidence ratio by facilitating timely medical intervention. Healthcare providers expect this launch to set a new standard for genomic profiling in India.

Frequently Asked Questions

Q1: Which cancer types does the Shield test cover?

The test covers various solid tumors, including gastric, esophageal, liver, colorectal, ovarian, lung, pancreatic, bladder, breast, and prostate cancers. For those interested in specialized diagnostic education, we recommend exploring our Certification Course In Clinical Oncology.

Q2: How does liquid biopsy differ from traditional biopsy?

Liquid biopsy detects tumor DNA via a simple blood draw, making it far less invasive than surgical tissue removal. Furthermore, it often provides a more comprehensive view of cancer mutations throughout the body.

References

1. Guardant Health to launch blood-based cancer test in India with ZydusLifesciences – ETHealthworld
2. Guardant Health. Shield Blood Test for Colorectal Cancer Screening.
3. U.S. Food and Drug Administration. FDA Approves First Blood Test for Colorectal Cancer Screening.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.